SANOFI ADR

NASDAQ: SNY (Sanofi)

Last update: 07 Jan, 10:10PM

48.37

0.20 (0.42%)

Previous Close 48.17
Open 47.88
Volume 3,011,297
Avg. Volume (3M) 2,434,931
Market Cap 117,189,836,800
Price / Earnings (TTM) 15.70
Price / Earnings (Forward) 9.69
Price / Sales 2.18
Price / Book 1.34
52 Weeks Range
44.62 (-7%) — 60.12 (24%)
Earnings Date 29 Jan 2026
TTM Dividend Yield 4.57%
Profit Margin 13.95%
Operating Margin (TTM) 20.78%
Diluted EPS (TTM) 2.94
Quarterly Revenue Growth (YOY) -4.60%
Quarterly Earnings Growth (YOY) 65.20%
Total Debt/Equity (MRQ) 23.01%
Current Ratio (MRQ) 1.46
Operating Cash Flow (TTM) 9.08 B
Levered Free Cash Flow (TTM) -4.94 B
Return on Assets (TTM) 4.28%
Return on Equity (TTM) 7.30%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock Sanofi Mixed Bearish

AIStockmoo Score

-1.0
Analyst Consensus 2.0
Insider Activity NA
Price Volatility -1.0
Technical Moving Averages -2.5
Technical Oscillators -2.5
Average -1.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SNY 117 B 4.57% 15.70 1.34
AZN 284 B 1.71% 30.63 6.38
AMGN 173 B 2.97% 24.80 18.50
GILD 154 B 2.54% 19.26 7.19
BIIB 26 B - 15.93 1.51
GRFS 8 B 1.88% 14.44 1.01

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Institutions 10.49%

Ownership

Name Date Shares Held
Mondrian Investment Partners Ltd 30 Sep 2025 3,638,606

No data within this time range.

No data within this time range.

Date Type Details
20 Jan 2026 CNBC Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
15 Jan 2026 Announcement Press Release: Myqorzo and Redemplo approved in China
15 Jan 2026 Announcement Press Release: Myqorzo and Redemplo approved in China
14 Jan 2026 Announcement Sanofi: Information concerning the total number of voting rights and shares - December 2025
12 Jan 2026 Announcement Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
12 Jan 2026 Announcement Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
05 Jan 2026 Announcement Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
05 Jan 2026 Announcement Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
24 Dec 2025 Announcement Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
24 Dec 2025 Announcement Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
24 Dec 2025 Announcement Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
24 Dec 2025 Announcement Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
23 Dec 2025 Announcement Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
23 Dec 2025 Announcement Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
23 Dec 2025 Announcement Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
23 Dec 2025 Announcement Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
22 Dec 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - November 2025
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
19 Dec 2025 Announcement Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
19 Dec 2025 Announcement Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
17 Dec 2025 Announcement Press release: Availability of the Q4 2025 Aide memoire
17 Dec 2025 Announcement Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
17 Dec 2025 Announcement Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
17 Dec 2025 Announcement Press release: Availability of the Q4 2025 Aide memoire
15 Dec 2025 Announcement Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
15 Dec 2025 Announcement Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
15 Dec 2025 Announcement Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
15 Dec 2025 Announcement Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
15 Dec 2025 Announcement Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
11 Dec 2025 Announcement Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
11 Dec 2025 Announcement Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
04 Dec 2025 Announcement Press Release: Sanofi completes acquisition of Vicebio
04 Dec 2025 Announcement Press Release: Sanofi completes acquisition of Vicebio
25 Nov 2025 Announcement Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
25 Nov 2025 Announcement Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
18 Nov 2025 Announcement Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
14 Nov 2025 Announcement Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
14 Nov 2025 Announcement Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
13 Nov 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares – October 2025
07 Nov 2025 Announcement Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
07 Nov 2025 Announcement Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
28 Oct 2025 Announcement Press release: Sanofi successfully prices USD 3 billion of bond issue
28 Oct 2025 Announcement Press release: Sanofi successfully prices USD 3 billion of bond issue
27 Oct 2025 Announcement UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
24 Oct 2025 Announcement Press release: Q3: continued sales and earnings progress
24 Oct 2025 Announcement Press release: Q3: continued sales and earnings progress
23 Oct 2025 Announcement Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
Show more
TTM Dividend Yield 4.57%
5Y Average Dividend Yield 4.99%
Payout Ratio 75.37%
Expected Next Dividend Payment Jun 2026
Ex Date Announcement Date Payment Date Details
09 May 2025 15 Apr 2025 12 Jun 2025 2.212154 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Cash
30 May 2023 - 23 Jun 2023 1.9000852 Cash
26 May 2022 - 27 Jun 2022 0.2971788 Cash
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Cash
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Cash
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Cash
07 May 2019 - 31 May 2019 1.722322 Cash
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Cash
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Cash
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Cash
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Cash
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Cash
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Cash
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Cash
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 2.21 1 4.57
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria